Drug intelligence / Profile preview

Cardiodoron

Development stage
Phase 4
Lead developer
Weleda
Modality
Small Molecules
Administration
Oral, Subcutaneous, Intravenous
01

Overview

Cardiodoron is an anthroposophic medicinal product developed by Weleda AG, specifically formulated for the treatment of functional cardiovascular disorders, hypotension, and orthostatic circulatory regulation disturbances. The medication is a combination of three plant-derived extracts: *Onopordum acanthium* (Cotton thistle), *Hyoscyamus niger* (Henbane), and *Primula veris* (Cowslip). In anthroposophic medicine, Cardiodoron is intended to stabilize and harmonize the rhythmic relationship between the cardiovascular and respiratory systems. It is commonly used to manage symptoms such as dizziness, fatigue, and circulatory weakness, particularly in patients with constitutional low blood pressure or during recovery from illness. The *Hyoscyamus niger* component provides a pharmacological basis for its action through tropane alkaloids that act as muscarinic receptor antagonists, while the other components contribute to its overall regulatory effect on the autonomic nervous system.

Brand names
Cardiodoron
Other names
Cardiodoron WeledaCardiodoron dropsCardiodoron injection

Beyond the preview

Go deeper on Cardiodoron.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiodoron.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call